Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical Officer
August 03, 2020 16:05 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Participate in Upcoming Investor Conferences
August 03, 2020 08:15 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter Financial Results and Recent Operational Highlights
July 30, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
July 28, 2020 06:00 ET
|
Selecta Biosciences, Inc.
STOCKHOLM, Sweden and WATERTOWN, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the strategic licensing agreement with Selecta...
Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases
June 18, 2020 08:30 ET
|
Selecta Biosciences, Inc.
CAMBRIDGE, Mass. and WATERTOWN, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, and Selecta Biosciences,...
Selecta Biosciences to Present at the Raymond James 2020 Human Healthcare Innovation Conference
June 15, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
June 11, 2020 17:15 ET
|
Selecta Biosciences, Inc.
- Strategic licensing agreement for SEL-212, a unique phase 3-ready therapy powered by Selecta’s breakthrough immune tolerance platform, ImmTOR™, with the potential to fulfil a significant unmet need...
Selecta Biosciences to Present at the Jefferies Virtual Healthcare Conference
May 26, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Reports First Quarter 2020 Financial Results
May 07, 2020 07:30 ET
|
Selecta Biosciences, Inc.
- Topline data announcement from the ongoing head-to-head COMPARE trial of SEL-212 remains on schedule for Q3 2020 - - Phase 3 clinical program of SEL-212 to commence in 2H 2020 - - Ongoing COVID-19...
Selecta Biosciences to Present at the Bank of America Merrill Lynch 2020 Health Care Conference
May 05, 2020 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...